# Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lifetime-cost-of-everolimus-vs-axitinib-in-patients-with-advanced-renal-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Allison Perrin,Steven Sherman,Sumanta K. Pal,Andrew Seng Boon Chua,Magdaliz Gorritz,Zhimei Liu,Xufang Wang,Kenneth W. Culver,Roman Casciano,Louis P. Garrison |
| Citations | 42 |
| DOI | 10.3111/13696998.2014.985789 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.tandfonline.com/doi/pdf/10.3111/13696998.2014.985789?download=true |
| OpenAlex ID | https://openalex.org/W1985943243 |
| PMID | 25422989 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Magdaliz Gorritz](https://scholariq.org/researchers/magdaliz-gorritz/)

## Paper journal

- [Journal of Medical Economics](https://scholariq.org/journals/journal-of-medical-economics/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.